Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck

Japanese Journal of Clinical Oncology

Volumn 44, Issue 5, 2014, Pages 416-421

  Komatsu, Masanori ^a   Shiono, Osamu ^b   Taguchi, Takahide ^a   Sakuma, Yasunori ^b   Nishimura, Goushi ^a   Sano, Daisuku ^a   Sakuma, Naoko ^a   Yabuki, Kenichiro ^a   Arai, Yasuhiro ^a   Takahashi, Masahiro ^a   Isitoya, Junichi ^b   Oridate, Nobuhiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

5 fluorouracil; Chemoradiotherapy; Cisplatin; Docetaxel; Head and neck squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INFECTION; KIDNEY DISEASE; LARYNX CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; 5-FLUOROURACIL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

5-FLUOROURACIL; CHEMORADIOTHERAPY; CISPLATIN; DOCETAXEL; HEAD AND NECK SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84902252083     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu026     Document Type: Article

References (23)

1. Clayman GL, Lipman SM, Laramore GE, et al. Head and neck neoplasms. In: Holland JF, Kufe DW, Pollock RE, et al. editors. Holland-Frei Cancer Medicine, 5th edn. Philadelphia, PA: BC Decker, 2000; 1173-220.
2. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995-1006.
3. Bourhis J, Maitre AL, Baujat B, Audry H, Pignon JP. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19:188-94.
4. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analysis of updated individual data. MACH-NC collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
5. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer. J Clin Oncol 2006;24:1064-71.
6. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction chemotherapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004;15:331-40.
7. Vermorken JB, Remenar E, Herpen CV, et al. Cisplatin, fluorouracil, and decetaxel in unresectable head and neck cancer. N Eng J Med 2007; 357:1695-704.
8. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Eng J Med 2007;357:1705-15.
9. Tsukuda M, Mikami Y, Tanigaki Y, et al. Phase 1 trial of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:161-6.
10. Katori H, Tsukuda M, Mochimatu I, et al. Phase 1 trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 2004;90:348-52.
11. Katori H, Tsukuda M. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 2005;17:148-52.
12. Tsukuda M, Ishitoya J, Matsuda H, et al. Randomized controlled phase II comparison study of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2010;66:729-36.
13. Furukawa S, Tsukuda M, Mochimatsu I, et al. Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck. Auris Nasus Larynx 1994;21:181-5.
14. World Health Organization. WHO Handbook for reporting results of cancer treatment. WHO offset publication No. 48. Geneva, Switzerland: World Health Organization 1979.
15. Brizel DM, Albers ME, Fisher SM, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
16. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GHORTEC). Int J Radiat Oncol Biol Phys 2006;64:983-94.
17. Haddad R, O'neill A, Robinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol 2013; 14:257-64.
18. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: update results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;64:1308-16.
19. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-73.
20. Homma A, Inamura N, Oridate N, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol 2011; 41:980-6.
21. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J med 2003;349:2091-8.
22. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-52.
23. Thomas JS, James K, Gary HL, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.